We used a Monte Carlo accept-reject method to find model parameters that reproduced our observations that, compared to progressed adenomas (A-CIA), benign adenomas (CRA) were: significantly more immunogenic (higher CD8 abundances, higher neoantigen recognition potentials, residing in spatial niche containing CD8 cells and M1 macrophages); had more immune blockade (PD-L1); similar levels of immunosuppressive cells/cytokines (CD68, CD163, IL-10, TGF-β) (data analyses in Figs. 5–8, Supplemental Figs. 9 and 11). This evidence concerns the gene CD163 and adenoma.